within Pharmacolibrary.Drugs.S_SensoryOrgans.S01A_Antiinfectives.S01AD08_Fomivirsen;
model Fomivirsen 
   extends Pharmacolibrary.Drugs.ATC.S.S01AD08;

  annotation(Documentation(
    info ="<html><body><p>Fomivirsen is an antisense oligonucleotide antiviral drug formerly used for the treatment of cytomegalovirus (CMV) retinitis in immunocompromised patients, such as those with AIDS. It inhibits CMV replication by binding to viral mRNA. Fomivirsen (Vitravene) was approved for intravitreal use but has been discontinued from the market.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters are poorly described in literature. Fomivirsen is administered via intravitreal injection, with very limited systemic absorption. Pharmacokinetic studies in humans showed slow elimination from the vitreous humor. Parameters are estimated based on available summaries.</p><h4>References</h4><ol><li><p>Geary, RS, et al., &amp; Grillone, LR (2002). Fomivirsen: clinical pharmacology and potential drug interactions. <i>Clinical pharmacokinetics</i> 41(4) 255–260. DOI:<a href=&quot;https://doi.org/10.2165/00003088-200241040-00002&quot;>10.2165/00003088-200241040-00002</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/11978144/&quot;>https://pubmed.ncbi.nlm.nih.gov/11978144</a></p></li><li><p>Leeds, JM, et al., &amp; Kornbrust, D (1997). Pharmacokinetics of a potential human cytomegalovirus therapeutic, a phosphorothioate oligonucleotide, after intravitreal injection in the rabbit. <i>Drug metabolism and disposition: the biological fate of chemicals</i> 25(8) 921–926. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/9280399/&quot;>https://pubmed.ncbi.nlm.nih.gov/9280399</a></p></li><li><p>del Amo, EM, et al., &amp; Urtti, A (2015). Intravitreal clearance and volume of distribution of compounds in rabbits: In silico prediction and pharmacokinetic simulations for drug development. <i>European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V</i> 95(Pt B) 215–226. DOI:<a href=&quot;https://doi.org/10.1016/j.ejpb.2015.01.003&quot;>10.1016/j.ejpb.2015.01.003</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/25603198/&quot;>https://pubmed.ncbi.nlm.nih.gov/25603198</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>",
    experiment(StartTime = 0, StopTime = 86400, Tolerance = 1e-09, Interval = 1)
  ));  
end Fomivirsen;
